Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-06-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（曹艳铭）
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of directors of 特一药业集团股份有限公司 nominating an independent director candidate. It contains detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and legal affirmations. There is no financial data, earnings information, or report publication mentioned. The content is focused on board/management information, specifically about a nomination to the board. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not a brief announcement or certification.
2022-06-10 Chinese
关于选举第五届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's fifth supervisory board. It includes details about the election process, the term, and the qualifications of the elected individual. There is no financial data, no mention of financial results, no audit information, no legal proceedings, no capital changes, and no shareholder voting results from a general meeting. The content focuses on management/board composition changes, specifically about the supervisory board member election and qualifications. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-06-10 Chinese
关于第四届董事会第二十八次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the 28th meeting of the 4th Board of Directors of 特一药业集团股份有限公司. It details the nomination and election of non-independent and independent directors for the 5th Board, voting results, and the scheduling of an extraordinary general meeting to approve these matters. The content focuses on board/management changes and related procedural announcements. There are no financial statements, audit information, or earnings data. The document is relatively short (2229 characters) and is a formal announcement of board decisions rather than a full report. Therefore, it fits best under the category of Board/Management Information (MANG).
2022-06-10 Chinese
关于非公开发行限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on non-publicly issued shares and their listing for trading. It includes specifics about the number of shares, shareholders involved, lock-up periods, regulatory approvals, and the shareholding structure before and after the lifting of restrictions. The document references approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is focused on the share issuance and capital structure changes related to restricted shares becoming tradable. There is no financial performance data, earnings information, or management discussion. The content fits the category of announcements related to share capital changes, specifically the lifting of restrictions on shares and their listing for trading. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief notice but a full announcement of capital change.
2022-05-29 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司非公开发行限售股份上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the lifting of trading restrictions on shares issued in a non-public offering by Te Yi Pharmaceutical Group Co., Ltd. It includes specifics about the share issuance, lock-up periods, shareholder commitments, and the shareholding structure before and after the lifting of restrictions. The document is not a financial report, earnings release, or management discussion but rather a formal verification and compliance opinion related to share issuance and listing rules. This fits the category of a Capital/Financing Update (CAP), as it deals with non-public issuance of shares and the subsequent lifting of restrictions on those shares, which is a capital structure change and financing activity update. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2022-05-29 Chinese
关于监事会换届选举的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the nomination and election process for the supervisory board (监事会) of a company, including candidate qualifications, nomination procedures, and related administrative details. It does not contain financial statements, audit results, or financial performance data. It is not a report of financial results or an annual report, nor is it a call transcript or capital update. The content focuses on board/management information, specifically about the supervisory board election and composition. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2022-05-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.